300016.SHE Beijing Beilu Pharmaceutical
- Market cap
- CNY 4.69B
- P/E
- 27.8x
- P/B
- 1.88x
- ROE
- 6.1%
- Dividend yield
- 0.80%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300016.SHE undervalued?
Graham number300016.SHE trades 52.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Beijing Beilu Pharmaceutical fundamental analysis
No fundamental analysis for Beijing Beilu Pharmaceutical yet.
Beijing Beilu Pharmaceutical stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Beijing Beilu Pharmaceutical
Beijing Beilu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. It provides contrast agents, such as Iohexol injection, Gadolinol injection, Gadopentetate Dimeglumine injection, Iodixanol injection, and Iopamidol injection; Jiuweizhenxin granule, a central nervous system product; and oral anti-diabetic drugs, including Glimepiride tablets and Repaglinide tablets. The company was founded in 1992 and is bas…
Full company profileBeijing Beilu Pharmaceutical financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Beijing Beilu Pharmaceutical annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 499M | 523M | 608M | 819M | 827M | 860M | 766M | 891M | 984M | 1.21B | 1.41B |
| Gross Profit | 344M | 340M | 407M | 564M | 547M | 532M | 400M | 405M | 459M | 552M | 581M |
| Operating Income | 17.1M | 142M | 167M | 400M | 183M | 127M | -13.3M | -100M | -596K | 102M | 200M |
| EBITDA | 43.1M | 158M | 185M | 418M | 221M | 231M | 109M | 33.3M | 148M | 246M | 198M |
| Net Income | 16.4M | 119M | 148M | 342M | 175M | 126M | 11.3M | -71.8M | 13.7M | 92.7M | 152M |
| EPS | 0.03 | 0.24 | 0.30 | 0.70 | 0.36 | 0.26 | 0.02 | -0.15 | 0.03 | 0.16 | 0.26 |
| Balance Sheet | |||||||||||
| Total Assets | 956M | 1.14B | 1.29B | 1.62B | 2.85B | 2.90B | 2.82B | 2.82B | 2.98B | 3.35B | 3.54B |
| Total Liabilities | 54.4M | 71.6M | 82.9M | 173M | 956M | 818M | 892M | 1.03B | 1.15B | 930M | 880M |
| Shareholders' Equity | 902M | 1.07B | 1.21B | 1.45B | 1.74B | 1.86B | 1.78B | 1.65B | 1.67B | 2.26B | 2.49B |
| Cash & Short-term Investments | 86.3M | 225M | 191M | 248M | 1.01B | 895M | 767M | 748M | 608M | 295M | 596M |
| Total Debt | - | - | - | 26.5M | 703M | 576M | 647M | 791M | 745M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 76.2M | 145M | 176M | 157M | 176M | 109M | 128M | 58.5M | 163M | 157M | - |
| Capital Expenditure | 44.2M | 55.0M | 54.1M | 35.0M | 172M | 148M | 103M | 145M | 101M | 219M | 121M |
| Free Cash Flow | 32.0M | 89.9M | 122M | 122M | 3.90M | -39.0M | 25.0M | -86.1M | 61.6M | -62.3M | 147M |
| Ratios | |||||||||||
| ROE | 1.8% | 11.1% | 12.3% | 23.6% | 10.0% | 6.8% | 0.6% | -4.3% | 0.8% | 4.1% | 6.1% |
| ROA | 1.7% | 10.4% | 11.5% | 21.1% | 6.1% | 4.3% | 0.4% | -2.5% | 0.5% | 2.8% | 4.3% |
| Net Profit Margin | 3.3% | 22.7% | 24.3% | 41.8% | 21.1% | 14.6% | 1.5% | -8.1% | 1.4% | 7.7% | 10.8% |
| Debt to Equity | - | - | - | 0.02x | 0.40x | 0.31x | 0.36x | 0.48x | 0.45x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Beijing Beilu Pharmaceutical dividends
- Dividend yield
- 0.80%
- Forward dividend
- 0.06 CNY
- Payout ratio
- 40.4%
- Ex-dividend date
- Sep 23, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 37.4M | 0.07 | 40.4% |
| 2024 | CNY 20.9M | 0.05 | 153.1% |
| 2023 | CNY 50.7M | 0.11 | - |
| 2022 | CNY 34.3M | 0.06 | 304.3% |
| 2021 | CNY 29.4M | 0.06 | 23.4% |
| 2020 | CNY 34.6M | 0.07 | 19.8% |
| 2019 | CNY 48.9M | 0.10 | 14.3% |
| 2018 | CNY 12.1M | 0.02 | 8.2% |
| 2017 | CNY 3.24M | 0.01 | 2.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.5:1 on Sep 4, 2018.
Who owns Beijing Beilu Pharmaceutical
- Insiders 28.39%
- Institutions 0.97%
- Public & others 70.64%
- Shares outstanding 582M
- Free float 436M
Beijing Beilu Pharmaceutical company profile
- Company name
- Beijing Beilu Pharmaceutical
- Ticker
- 300016.SHE
- ISIN
- CNE000001QK9
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Oct 30, 2009
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,188
- Fiscal year end
- December
- Address
- Maples International Office, Beijing, China, 100082
- Phone
- 86 10 6262 2266
- Website
- beilu.com.cn
About Beijing Beilu Pharmaceutical
Beijing Beilu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. It provides contrast agents, such as Iohexol injection, Gadolinol injection, Gadopentetate Dimeglumine injection, Iodixanol injection, and Iopamidol injection; Jiuweizhenxin granule, a central nervous system product; and oral anti-diabetic drugs, including Glimepiride tablets and Repaglinide tablets. The company was founded in 1992 and is based in Beijing, China.
Beijing Beilu Pharmaceutical management
7- Mr. Xu WangChairman & GM · born 1984
- Ms. Ni Zeng CPADeputy GM, CFO, Accounting Supervisor & Non-Independent Director · born 1992
- Mr. Sen LiExecutive VP & COO · born 1981
- Ms. Li ZongDeputy General Manager · born 1971
- Ms. Zehui ShaoDeputy GM, Secretary of the Board of Directors & Non-Independent Director · born 1980
- Ms. Xiasi KuangDeputy General Manager · born 1982
- Mr. Gen Chang ZhengChief Engineer & Employee Representative Member of Supervisory Board · born 1969